0 Ratings
ID

32650

Description

This ODM file contains the form to document all serious events that are temporally associated with the use of the study medication. Study ID: 101999 Clinical Study ID: 101999 Study Title: A randomized, double-blind, parallel group, placebo-controlled, single-attack evaluation of the efficacy and tolerability of TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg)* tablets vs placebo when administered during the mild pain phase of a migraine Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: sumatriptan Trade Name: Imitrex ,Imiject ,Imigran Study Indication: Migraine Disorders

Keywords

Versions (2)
  1. 11/6/18 11/6/18 -
  2. 11/9/18 11/9/18 -
Copyright Holder

GlaxoSmithKline

Uploaded on

November 9, 2018

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

  • Newest
  • Oldest
  • Popular
  • Newest
    • Newest
    • Oldest
    • Popular

    No comments

    In order to download data models you must be logged in. Please log in or register for free.

    Efficacy and Tolerability of TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg) ID 101999

    English

    Serious Adverse Event

    1 forms  
    1. StudyEvent: ODM
      1. Serious Adverse Event
    Administrative Data
    Description

    Administrative Data

    Alias
    UMLS CUI-1
    C1320722
    Subject Identifier
    Description

    Subject Identifier

    Data type

    text

    Alias
    UMLS CUI [1]
    C2348585
    Centre Number
    Description

    Centre Number

    Data type

    text

    Alias
    UMLS CUI [1,1]
    C0600091
    UMLS CUI [1,2]
    C0019994
    Randomisation Number
    Description

    Randomisation Number

    Data type

    text

    Alias
    UMLS CUI [1,1]
    C0034656
    UMLS CUI [1,2]
    C0237753
    Serious Adverse Event
    Description

    Serious Adverse Event

    Alias
    UMLS CUI-1
    C1519255
    Did the subject experience a serious adverse event during the study?
    Description

    DEFINITION OF A SERIOUS ADVERSE EVENT (SAE) (Page 1 of 5) A serious adverse event is any untoward medical occurrence that, at any dose: a) results in death. b) is life-threatening. Note: The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe. c) requires hospitalisation or prolongation of existing hospitalisation. Note: In general, hospitalisation signifies that the subject has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician’s office or out-patient setting. Complications that occur during hospitalisation are AEs. If a complication prolongs hospitalisation or fulfils any other serious criteria, the event is ’serious’. When in doubt as to whether ’hospitalisation’ occurred or was necessary, the AE should be considered ’serious’. Hospitalisation for elective treatment of a preexisting condition that did not worsen from baseline is not considered an AE. d) results in disability/incapacity, or Note: The term disability means a substantial disruption of a person’s ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma (e.g., sprained ankle) which may interfere or prevent everyday life functions but do not constitute a substantial disruption. e) is a congenital anomaly/birth defect. f) other. Medical or scientific judgement should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation, or development of drug dependency or drug abuse.

    Data type

    text

    Alias
    UMLS CUI [1]
    C1519255
    If fatal, was a post-mortem/autopsy performed If Yes, summarise findings in Section 11 Narrative Remarks of this SAE form.
    Description

    If Yes, summarise findings in Section 11 Narrative Remarks of this SAE form.

    Data type

    text

    Alias
    UMLS CUI [1,1]
    C0004398
    UMLS CUI [1,2]
    C1519255
    SECTION 1
    Description

    SECTION 1

    Alias
    UMLS CUI-1
    C1828479
    UMLS CUI-2
    C1519255
    Diagnosis Only (if known) Otherwise Sign/Symptom
    Description

    Record one SAE diagnosis per line, or a sign/symptom if the diagnosis is not available. If a diagnosis subsequently becomes available, this then should be entered and the sign/symptom crossed out, initialled and dated by the investigator. A separate form should be used for each SAE. However, if multiple SAEs which are temporally or clinically related are apparent at the time of initial reporting then these may be reported on the same page.

    Data type

    text

    Alias
    UMLS CUI [1,1]
    C0011900
    UMLS CUI [1,2]
    C1519255
    Start Date
    Description

    Record the start date of the first occurrence of the SAE.

    Data type

    date

    Alias
    UMLS CUI [1,1]
    C0808070
    UMLS CUI [1,2]
    C1519255
    Start Time
    Description

    Start Time of Serious Adverse Event

    Data type

    time

    Alias
    UMLS CUI [1,1]
    C1301880
    UMLS CUI [1,2]
    C1519255
    Outcome
    Description

    All SAEs must be followed until the events are resolved, the condition stabilises, the events are otherwise explained, or the subject is lost to follow-up. Indicate if the event was ’Recovered/Resolved’ or ’Recovered/Resolved with sequelae’. If the SAE is ongoing at the time the subject completes the study or becomes lost to follow-up, the outcome must be recorded as ’Not recovered/Not resolved’ or ’Recovering/Resolving’. Also enter ’Not recovered/Not resolved’ if the SAE was ongoing at the time of death, but was not the cause of death, enter fatal for the SAE which was the direct cause of death.

    Data type

    integer

    Alias
    UMLS CUI [1,1]
    C1705586
    UMLS CUI [1,2]
    C1519255
    End Date
    Description

    Record the end date. This is the date the SAE Recovered/Resolved, or if the outcome was fatal, record the date the subject died. If the event Recovered/ Resolved with sequelae, enter the date the subject’s medical condition resolved or stabilised. Leave blank if the SAE is ’Not recovered/Not resolved’ or ’Recovering/Resolving’.

    Data type

    date

    Alias
    UMLS CUI [1,1]
    C0806020
    UMLS CUI [1,2]
    C1519255
    End Time
    Description

    End Time of Serious Adverse Event

    Data type

    time

    Alias
    UMLS CUI [1,1]
    C1522314
    UMLS CUI [1,2]
    C1519255
    Maximum Intensity
    Description

    Record the maximum intensity that occurred over the duration of the event. Amend the intensity if it increases. Mild = An event that is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities. Moderate = An event that is sufficiently discomforting to interfere with everyday activities. Severe = An event that prevents normal everyday activities. Not applicable = Those event(s) where intensity is meaningless or impossible to determine (i.e., blindness and coma).

    Data type

    text

    Alias
    UMLS CUI [1,1]
    C1710056
    UMLS CUI [1,2]
    C1519255
    Actions taken with Investigational Product(s) as a Result of the SAE
    Description

    Investigational product(s) withdrawn = Dose reduced = Dose increased = Dose not changed = Dose interrupted = Not applicable = Administration of investigational product(s) was permanently discontinued. Dose is reduced for one or more investigational product(s). Dose increased for one or more investigational product(s). Investigational product(s) continues even though an adverse event has occurred. Administration of one or more investigational product(s) was temporarily interrupted but then restarted. Subject was not receiving investigational product(s) when the event occurred (e.g., pre-or post-dosing) or the subject died and there was no prior decision to discontinue IP(s).

    Data type

    text

    Alias
    UMLS CUI [1,1]
    C1704758
    UMLS CUI [1,2]
    C1519255
    Did the subject withdraw from study as a result of this SAE? If yes: Complete Study Conclusion page and tick Adverse event as reason for withdrawal.
    Description

    Indicate ’Yes’ if the event(s) were directly responsible for the subject’s withdrawal as indicated on the Study Conclusion page, otherwise indicate ’No’. If yes: Complete Study Conclusion page and check Adverse event as reason for withdrawal.

    Data type

    text

    Alias
    UMLS CUI [1,1]
    C0422727
    UMLS CUI [1,2]
    C1519255
    Is there a reasonable possibility the SAE may have been caused by the investigational product?
    Description

    It is a regulatory requirement for investigators to assess relationship to investigational product(s) based on information available. The assessment should be reviewed on receipt of any new information and amended if necessary. ’A reasonable possibility’ is meant to convey that there are facts/evidence or arguments to suggest a causal relationship. Facts/evidence or arguments that may support ’a reasonable possibility’ include, e.g., a temporal relationship, a pharmacologically-predicted event, or positive dechallenge or rechallenge. Confounding factors, such as concomitant medication, a concurrent illness, or relevant medical history, should also be considered.

    Data type

    text

    Alias
    UMLS CUI [1,1]
    C0085978
    UMLS CUI [1,2]
    C1519255
    SECTION 2: Seriousness
    Description

    SECTION 2: Seriousness

    Alias
    UMLS CUI-1
    C1828479
    UMLS CUI-2
    C1710056
    [A] Results in death
    Description

    SAE results in death

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C1705232
    UMLS CUI [1,2]
    C1519255
    [B] Is life-threatening
    Description

    SAE is life-threatening

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C1517874
    UMLS CUI [1,2]
    C1519255
    [C] Requires hospitalisation or prolongation of existing hospitalisation
    Description

    SAE requires hospitalisation

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C2826664
    UMLS CUI [1,2]
    C1519255
    [D] Results in disability/incapacity
    Description

    SAE results in disability/incapacity

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C1519255
    UMLS CUI [1,2]
    C0231170
    [E] Congenital anomaly/birth defect
    Description

    Congenital anomaly/birth defect

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C0000768
    UMLS CUI [1,2]
    C1519255
    [F] Other
    Description

    SAE, other

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C1519255
    UMLS CUI [1,2]
    C1880177
    Other, specify
    Description

    (see definition of SAE)

    Data type

    text

    Alias
    UMLS CUI [1,1]
    C3845569
    UMLS CUI [1,2]
    C1519255
    SECTION 3 Demography Data
    Description

    SECTION 3 Demography Data

    Alias
    UMLS CUI-1
    C1828479
    UMLS CUI-2
    C0011298
    Date of birth
    Description

    Date of birth

    Data type

    date

    Alias
    UMLS CUI [1]
    C0421451
    Sex
    Description

    Sex

    Data type

    text

    Alias
    UMLS CUI [1]
    C0079399
    Weight
    Description

    Weight

    Data type

    float

    Measurement units
    • kg
    Alias
    UMLS CUI [1]
    C0005910
    kg
    SECTION 4 If Investigational Product(s) was Stopped, Did the Reported Event(s) Recur After Further Investigational Product(s) were Administered?
    Description

    SECTION 4 If Investigational Product(s) was Stopped, Did the Reported Event(s) Recur After Further Investigational Product(s) were Administered?

    Alias
    UMLS CUI-1
    C0877248
    UMLS CUI-2
    C0034897
    If Investigational Product(s) was Stopped, Did the Reported Event(s) Recur After Further Investigational Product(s) were Administered?
    Description

    Recurrence of the reported SAE in case of discontinuation of the investigational product

    Data type

    text

    Alias
    UMLS CUI [1,1]
    C1519255
    UMLS CUI [1,2]
    C0034897
    UMLS CUI [1,3]
    C0304229
    UMLS CUI [1,4]
    C0457454
    SECTION 5 Possible Causes of SAE Other Than Investigational Product(s)
    Description

    SECTION 5 Possible Causes of SAE Other Than Investigational Product(s)

    Alias
    UMLS CUI-1
    C1828479
    UMLS CUI-2
    C0085978
    UMLS CUI-3
    C1710056
    Disease under study
    Description

    Disease under study

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C0012634
    UMLS CUI [1,2]
    C0347984
    UMLS CUI [1,3]
    C0008976
    Medical condition(s) (record in Section 6)
    Description

    Medical condition(s)

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0012634
    Lack of efficacy
    Description

    Lack of efficacy

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0235828
    Withdrawal of investigational product(s)
    Description

    Withdrawal of investigational product(s)

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C2349954
    UMLS CUI [1,2]
    C0013227
    Concomitant medication(s) (record in Section 8)
    Description

    Concomitant medication(s)

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C2347852
    Activity related to study participation (e.g., procedures)
    Description

    Activity related to study participation

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C2348568
    Other, specify
    Description

    Other, specify

    Data type

    text

    Alias
    UMLS CUI [1,1]
    C0205394
    UMLS CUI [1,2]
    C1521902
    SECTION 6 RELEVANT Medical Conditions
    Description

    SECTION 6 RELEVANT Medical Conditions

    Alias
    UMLS CUI-1
    C0262926
    UMLS CUI-2
    C1828479
    Specify any RELEVANT past or current medical disorders, allergies, surgeries, etc. that can help explain the SAE
    Description

    Relevant Medical Conditions

    Data type

    text

    Alias
    UMLS CUI [1,1]
    C0012634
    UMLS CUI [1,2]
    C0262926
    UMLS CUI [1,3]
    C1519255
    Date of onset
    Description

    Date of onset

    Data type

    date

    Alias
    UMLS CUI [1]
    C0574845
    Condition Present at Time of the SAE?
    Description

    Continuation SAE

    Data type

    text

    Alias
    UMLS CUI [1,1]
    C0805733
    UMLS CUI [1,2]
    C1519255
    If No, Date of Last Occurrence
    Description

    Date of Last Occurrence

    Data type

    date

    Alias
    UMLS CUI [1,1]
    C0011008
    UMLS CUI [1,2]
    C2745955
    SECTION 7 Other RELEVANT Risk Factors
    Description

    SECTION 7 Other RELEVANT Risk Factors

    Alias
    UMLS CUI-1
    C0035648
    UMLS CUI-2
    C1519255
    UMLS CUI-3
    C0205394
    Other RELEVANT Risk Factors
    Description

    (provide any family or social history (e.g., smoking, alcohol, diet, drug abuse, occupational hazard) relevant to the SAE)

    Data type

    text

    Alias
    UMLS CUI [1]
    C0035648
    SECTION 8 RELEVANT Concomitant Medications
    Description

    SECTION 8 RELEVANT Concomitant Medications

    Alias
    UMLS CUI-1
    C1828479
    UMLS CUI-2
    C2347852
    Drug Name
    Description

    (Trade Name preferred)

    Data type

    text

    Alias
    UMLS CUI [1]
    C0013227
    Dose
    Description

    Dose

    Data type

    float

    Alias
    UMLS CUI [1]
    C3174092
    Unit
    Description

    Unit

    Data type

    text

    Alias
    UMLS CUI [1]
    C1519795
    Frequency
    Description

    Frequency

    Data type

    text

    Alias
    UMLS CUI [1]
    C3476109
    Route
    Description

    Route

    Data type

    text

    Alias
    UMLS CUI [1]
    C0013153
    Taken Prior to Study?
    Description

    Taken Prior to Study?

    Data type

    text

    Alias
    UMLS CUI [1]
    C2826667
    Start Date
    Description

    Start Date

    Data type

    date

    Alias
    UMLS CUI [1]
    C0808070
    Stop Date
    Description

    Stop Date

    Data type

    date

    Alias
    UMLS CUI [1]
    C0806020
    Ongoing Medication?
    Description

    Ongoing Medication?

    Data type

    text

    Alias
    UMLS CUI [1]
    C2826666
    Reason for Medication
    Description

    Reason for Medication

    Data type

    text

    Alias
    UMLS CUI [1,1]
    C0392360
    UMLS CUI [1,2]
    C0013227
    SECTION 9 Details of Investigational Product(s)
    Description

    SECTION 9 Details of Investigational Product(s)

    Alias
    UMLS CUI-1
    C1828479
    UMLS CUI-2
    C0013230
    UMLS CUI-3
    C1522508
    Date study medication taken
    Description

    Date study medication taken

    Data type

    date

    Alias
    UMLS CUI [1,1]
    C0304229
    UMLS CUI [1,2]
    C0011008
    Time study medication taken
    Description

    Time study medication taken

    Data type

    time

    Alias
    UMLS CUI [1,1]
    C0304229
    UMLS CUI [1,2]
    C0040223
    Was randomisation code broken at investigational site?
    Description

    Randomisation code broken at investigational site

    Data type

    text

    Alias
    UMLS CUI [1,1]
    C0034656
    UMLS CUI [1,2]
    C3899531
    SECTION 10 Details of relevant Assessments
    Description

    SECTION 10 Details of relevant Assessments

    Alias
    UMLS CUI-1
    C1828479
    UMLS CUI-2
    C0011900
    UMLS CUI-3
    C1519255
    Details of RELEVANT Assessments (provide details of any other tests/procedures which were carried out to diagnose or confirm the SAE e.g., laboratory data with units and normal range)
    Description

    Details of relevant assessments

    Data type

    text

    Alias
    UMLS CUI [1,1]
    C1261322
    UMLS CUI [1,2]
    C1519255
    SECTION 11 Narrative Remarks
    Description

    SECTION 11 Narrative Remarks

    Alias
    UMLS CUI-1
    C1828479
    UMLS CUI-2
    C0947611
    Narrative Remarks (provide a brief narrative description of the SAE and details of treatment given)
    Description

    Narrative Remarks

    Data type

    text

    Alias
    UMLS CUI [1,1]
    C0947611
    UMLS CUI [1,2]
    C1519255
    Investigator's name and signature
    Description

    Investigator's name and signature

    Alias
    UMLS CUI-1
    C2826892
    UMLS CUI-3
    C2346576
    Investigator's signature (confirming that the data on the SAE pages are accurate and complete)
    Description

    Investigator's signature

    Data type

    text

    Alias
    UMLS CUI [1]
    C2346576
    Investigator’s name (print)
    Description

    Investigator’s name

    Data type

    text

    Alias
    UMLS CUI [1]
    C2826892
    Date
    Description

    Date

    Data type

    date

    Alias
    UMLS CUI [1]
    C0011008
    Back to the top of the page

    Similar models

    Serious Adverse Event

    1 forms
    1. StudyEvent: ODM
      1. Serious Adverse Event
    Name
    Type
    Description | Question | Decode (Coded Value)
    Data type
    Alias
    Item Group
    Administrative Data
    C1320722 (UMLS CUI-1)
    Subject Identifier
    Item
    Subject Identifier
    text
    C2348585 (UMLS CUI [1])
    Centre Number
    Item
    Centre Number
    text
    C0600091 (UMLS CUI [1,1])
    C0019994 (UMLS CUI [1,2])
    Randomisation Number
    Item
    Randomisation Number
    text
    C0034656 (UMLS CUI [1,1])
    C0237753 (UMLS CUI [1,2])
    Item Group
    Serious Adverse Event
    C1519255 (UMLS CUI-1)
    Item
    Did the subject experience a serious adverse event during the study?
    text
    C1519255 (UMLS CUI [1])
    Did the subject experience a serious adverse event during the study?
    Code List
    Did the subject experience a serious adverse event during the study?
    CL Item
    Yes (Y)
    CL Item
    No (N)
    Item
    If fatal, was a post-mortem/autopsy performed If Yes, summarise findings in Section 11 Narrative Remarks of this SAE form.
    text
    C0004398 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    Autopsy after serious event
    Code List
    If fatal, was a post-mortem/autopsy performed If Yes, summarise findings in Section 11 Narrative Remarks of this SAE form.
    CL Item
    Yes (Y)
    CL Item
    No (N)
    Item Group
    SECTION 1
    C1828479 (UMLS CUI-1)
    C1519255 (UMLS CUI-2)
    Event
    Item
    Diagnosis Only (if known) Otherwise Sign/Symptom
    text
    C0011900 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    Start Date of the Serious Adverse Event
    Item
    Start Date
    date
    C0808070 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    Start Time of Serious Adverse Event
    Item
    Start Time
    time
    C1301880 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    Item
    Outcome
    integer
    C1705586 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    Outcome
    Code List
    Outcome
    CL Item
    Recovered/Resolved (1)
    CL Item
    Recovering/Resolving (2)
    CL Item
    Not recovered/Not resolved (3)
    CL Item
    Recovered/Resolved with sequelae (4)
    CL Item
    Fatal (5)
    End Date of Serious Adverse Event
    Item
    End Date
    date
    C0806020 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    End Time of Serious Adverse Event
    Item
    End Time
    time
    C1522314 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    Item
    Maximum Intensity
    text
    C1710056 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    Maximum Intensity
    Code List
    Maximum Intensity
    CL Item
    Mild (1)
    CL Item
    Moderate (2)
    CL Item
    Severe (3)
    CL Item
    Not applicable (X)
    Item
    Actions taken with Investigational Product(s) as a Result of the SAE
    text
    C1704758 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    Actions taken with Investigational Product(s) as a Result of the SAE
    Code List
    Actions taken with Investigational Product(s) as a Result of the SAE
    CL Item
    Investigational product(s) withdrawn (1)
    CL Item
    Dose reduced (2)
    CL Item
    Doce increased (3)
    CL Item
    Dose not changed (4)
    CL Item
    Dose interrupted (5)
    CL Item
    Not applicable (X)
    Item
    Did the subject withdraw from study as a result of this SAE? If yes: Complete Study Conclusion page and tick Adverse event as reason for withdrawal.
    text
    C0422727 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    Did the subject withdraw from study as a result of this SAE?
    Code List
    Did the subject withdraw from study as a result of this SAE? If yes: Complete Study Conclusion page and tick Adverse event as reason for withdrawal.
    CL Item
    No (N)
    CL Item
    Yes (Y)
    Item
    Is there a reasonable possibility the SAE may have been caused by the investigational product?
    text
    C0085978 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    Is there a reasonable possibility the SAE may have been caused by the investigational product?
    Code List
    Is there a reasonable possibility the SAE may have been caused by the investigational product?
    CL Item
    Yes (Y)
    CL Item
    No (N)
    Item Group
    SECTION 2: Seriousness
    C1828479 (UMLS CUI-1)
    C1710056 (UMLS CUI-2)
    SAE results in death
    Item
    [A] Results in death
    boolean
    C1705232 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    SAE is life-threatening
    Item
    [B] Is life-threatening
    boolean
    C1517874 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    SAE requires hospitalisation
    Item
    [C] Requires hospitalisation or prolongation of existing hospitalisation
    boolean
    C2826664 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    SAE results in disability/incapacity
    Item
    [D] Results in disability/incapacity
    boolean
    C1519255 (UMLS CUI [1,1])
    C0231170 (UMLS CUI [1,2])
    Congenital anomaly/birth defect
    Item
    [E] Congenital anomaly/birth defect
    boolean
    C0000768 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    SAE, other
    Item
    [F] Other
    boolean
    C1519255 (UMLS CUI [1,1])
    C1880177 (UMLS CUI [1,2])
    SAE, other: specification
    Item
    Other, specify
    text
    C3845569 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    Item Group
    SECTION 3 Demography Data
    C1828479 (UMLS CUI-1)
    C0011298 (UMLS CUI-2)
    Date of birth
    Item
    Date of birth
    date
    C0421451 (UMLS CUI [1])
    Item
    Sex
    text
    C0079399 (UMLS CUI [1])
    Sex
    Code List
    Sex
    CL Item
    Male (Male)
    CL Item
    Female (Female)
    Weight
    Item
    Weight
    float
    C0005910 (UMLS CUI [1])
    Item Group
    SECTION 4 If Investigational Product(s) was Stopped, Did the Reported Event(s) Recur After Further Investigational Product(s) were Administered?
    C0877248 (UMLS CUI-1)
    C0034897 (UMLS CUI-2)
    Item
    If Investigational Product(s) was Stopped, Did the Reported Event(s) Recur After Further Investigational Product(s) were Administered?
    text
    C1519255 (UMLS CUI [1,1])
    C0034897 (UMLS CUI [1,2])
    C0304229 (UMLS CUI [1,3])
    C0457454 (UMLS CUI [1,4])
    If Investigational Product(s) was Stopped, Did the Reported Event(s) Recur After Further Investigational Product(s) were Administered?
    Code List
    If Investigational Product(s) was Stopped, Did the Reported Event(s) Recur After Further Investigational Product(s) were Administered?
    CL Item
    Yes (Yes)
    CL Item
    No (No)
    CL Item
    Unknown at this time (Unknown at this time)
    CL Item
    Not applicable (Not applicable)
    Item Group
    SECTION 5 Possible Causes of SAE Other Than Investigational Product(s)
    C1828479 (UMLS CUI-1)
    C0085978 (UMLS CUI-2)
    C1710056 (UMLS CUI-3)
    Disease under study
    Item
    Disease under study
    boolean
    C0012634 (UMLS CUI [1,1])
    C0347984 (UMLS CUI [1,2])
    C0008976 (UMLS CUI [1,3])
    Medical condition(s)
    Item
    Medical condition(s) (record in Section 6)
    boolean
    C0012634 (UMLS CUI [1])
    Lack of efficacy
    Item
    Lack of efficacy
    boolean
    C0235828 (UMLS CUI [1])
    Withdrawal of investigational product(s)
    Item
    Withdrawal of investigational product(s)
    boolean
    C2349954 (UMLS CUI [1,1])
    C0013227 (UMLS CUI [1,2])
    Concomitant medication(s)
    Item
    Concomitant medication(s) (record in Section 8)
    boolean
    C2347852 (UMLS CUI [1])
    Activity related to study participation
    Item
    Activity related to study participation (e.g., procedures)
    boolean
    C2348568 (UMLS CUI [1])
    Other, specify
    Item
    Other, specify
    text
    C0205394 (UMLS CUI [1,1])
    C1521902 (UMLS CUI [1,2])
    Item Group
    SECTION 6 RELEVANT Medical Conditions
    C0262926 (UMLS CUI-1)
    C1828479 (UMLS CUI-2)
    Relevant Medical Conditions
    Item
    Specify any RELEVANT past or current medical disorders, allergies, surgeries, etc. that can help explain the SAE
    text
    C0012634 (UMLS CUI [1,1])
    C0262926 (UMLS CUI [1,2])
    C1519255 (UMLS CUI [1,3])
    Date of onset
    Item
    Date of onset
    date
    C0574845 (UMLS CUI [1])
    Item
    Condition Present at Time of the SAE?
    text
    C0805733 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    Condition Present at Time of the SAE
    Code List
    Condition Present at Time of the SAE?
    CL Item
    Yes (Y)
    CL Item
    No (N)
    Date of Last Occurrence
    Item
    If No, Date of Last Occurrence
    date
    C0011008 (UMLS CUI [1,1])
    C2745955 (UMLS CUI [1,2])
    Item Group
    SECTION 7 Other RELEVANT Risk Factors
    C0035648 (UMLS CUI-1)
    C1519255 (UMLS CUI-2)
    C0205394 (UMLS CUI-3)
    Other RELEVANT Risk Factors
    Item
    Other RELEVANT Risk Factors
    text
    C0035648 (UMLS CUI [1])
    Item Group
    SECTION 8 RELEVANT Concomitant Medications
    C1828479 (UMLS CUI-1)
    C2347852 (UMLS CUI-2)
    Drug Name
    Item
    Drug Name
    text
    C0013227 (UMLS CUI [1])
    Dose
    Item
    Dose
    float
    C3174092 (UMLS CUI [1])
    Unit
    Item
    Unit
    text
    C1519795 (UMLS CUI [1])
    Frequency
    Item
    Frequency
    text
    C3476109 (UMLS CUI [1])
    Route
    Item
    Route
    text
    C0013153 (UMLS CUI [1])
    Item
    Taken Prior to Study?
    text
    C2826667 (UMLS CUI [1])
    Taken Prior to Study?
    Code List
    Taken Prior to Study?
    CL Item
    Yes (Y)
    CL Item
    No (N)
    Start Date
    Item
    Start Date
    date
    C0808070 (UMLS CUI [1])
    Stop Date
    Item
    Stop Date
    date
    C0806020 (UMLS CUI [1])
    Item
    Ongoing Medication?
    text
    C2826666 (UMLS CUI [1])
    Ongoing Medication?
    Code List
    Ongoing Medication?
    CL Item
    Yes (Y)
    CL Item
    No (N)
    Reason for Medication
    Item
    Reason for Medication
    text
    C0392360 (UMLS CUI [1,1])
    C0013227 (UMLS CUI [1,2])
    Item Group
    SECTION 9 Details of Investigational Product(s)
    C1828479 (UMLS CUI-1)
    C0013230 (UMLS CUI-2)
    C1522508 (UMLS CUI-3)
    Date study medication taken
    Item
    Date study medication taken
    date
    C0304229 (UMLS CUI [1,1])
    C0011008 (UMLS CUI [1,2])
    Time study medication taken
    Item
    Time study medication taken
    time
    C0304229 (UMLS CUI [1,1])
    C0040223 (UMLS CUI [1,2])
    Item
    Was randomisation code broken at investigational site?
    text
    C0034656 (UMLS CUI [1,1])
    C3899531 (UMLS CUI [1,2])
    Randomisation code broken at investigational site
    Code List
    Was randomisation code broken at investigational site?
    CL Item
    Yes (Yes)
    CL Item
    No (No)
    CL Item
    Not applicable (Not applicable)
    Item Group
    SECTION 10 Details of relevant Assessments
    C1828479 (UMLS CUI-1)
    C0011900 (UMLS CUI-2)
    C1519255 (UMLS CUI-3)
    Details of relevant assessments
    Item
    Details of RELEVANT Assessments (provide details of any other tests/procedures which were carried out to diagnose or confirm the SAE e.g., laboratory data with units and normal range)
    text
    C1261322 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    Item Group
    SECTION 11 Narrative Remarks
    C1828479 (UMLS CUI-1)
    C0947611 (UMLS CUI-2)
    Narrative Remarks
    Item
    Narrative Remarks (provide a brief narrative description of the SAE and details of treatment given)
    text
    C0947611 (UMLS CUI [1,1])
    C1519255 (UMLS CUI [1,2])
    Item Group
    Investigator's name and signature
    C2826892 (UMLS CUI-1)
    C2346576 (UMLS CUI-3)
    Investigator's signature
    Item
    Investigator's signature (confirming that the data on the SAE pages are accurate and complete)
    text
    C2346576 (UMLS CUI [1])
    Investigator’s name
    Item
    Investigator’s name (print)
    text
    C2826892 (UMLS CUI [1])
    Date
    Item
    Date
    date
    C0011008 (UMLS CUI [1])
    Back to the top of the page 

    Help

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial